David D. O’toole Buys 975 Shares of AVITA Medical, Inc. (NASDAQ:RCEL) Stock

AVITA Medical, Inc. (NASDAQ:RCEL) CFO David D. O’toole purchased 975 shares of AVITA Medical stock in a transaction dated Thursday, December 5th. The shares were bought at an average price of $12.46 per share, with a total value of $12,148.50. Following the completion of the transaction, the chief financial officer now owns 23,734 shares in the company, valued at approximately $295,725.64. This trade represents a 4.28 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

AVITA Medical Stock Performance

Shares of RCEL opened at $12.44 on Friday. AVITA Medical, Inc. has a 12-month low of $7.51 and a 12-month high of $18.93. The stock has a market cap of $326.18 million, a P/E ratio of -5.58 and a beta of 1.60. The company has a current ratio of 3.73, a quick ratio of 3.37 and a debt-to-equity ratio of 3.48. The company has a 50-day moving average of $11.48 and a two-hundred day moving average of $9.91.

AVITA Medical (NASDAQ:RCEL) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.21). AVITA Medical had a negative return on equity of 194.69% and a negative net margin of 95.47%. The company had revenue of $19.55 million for the quarter, compared to analyst estimates of $19.65 million. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. As a group, research analysts predict that AVITA Medical, Inc. will post -2.35 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RCEL has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $21.00 price objective on shares of AVITA Medical in a report on Friday, August 9th. Piper Sandler restated a “neutral” rating and issued a $12.00 price target (up previously from $9.00) on shares of AVITA Medical in a research report on Friday, November 8th.

Institutional Trading of AVITA Medical

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in AVITA Medical by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,408,136 shares of the company’s stock worth $22,572,000 after purchasing an additional 15,356 shares in the last quarter. Geode Capital Management LLC lifted its holdings in AVITA Medical by 1.4% in the 3rd quarter. Geode Capital Management LLC now owns 594,436 shares of the company’s stock valued at $6,373,000 after purchasing an additional 8,361 shares in the last quarter. State Street Corp boosted its stake in shares of AVITA Medical by 2.4% during the 3rd quarter. State Street Corp now owns 519,997 shares of the company’s stock worth $5,574,000 after purchasing an additional 11,997 shares during the last quarter. Essex Investment Management Co. LLC purchased a new stake in shares of AVITA Medical during the third quarter worth about $2,477,000. Finally, Jane Street Group LLC raised its position in shares of AVITA Medical by 32.7% in the third quarter. Jane Street Group LLC now owns 89,395 shares of the company’s stock valued at $958,000 after buying an additional 22,032 shares during the last quarter. 27.66% of the stock is currently owned by hedge funds and other institutional investors.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.